Navigation Links
Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 6, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 102, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic hepatitis B virus (HBV) infection, met its primary efficacy endpoint. The study shows that Viread is non-inferior to the company's once-daily antiviral drug Hepsera(R) (adefovir dipivoxil) among patients with HBeAg-negative/anti-HBe positive (presumed pre-core mutant) chronic HBV infection. The primary efficacy endpoint, the proportion of patients with a complete response at week 48, was defined by serum HBV DNA levels below 400 copies/mL and histologic improvement characterized by at least a two point reduction in the Knodell necroinflammatory score (a measure of necro-inflammation - an inflammatory process in the liver including or leading to death of liver cells) with no concurrent worsening of fibrosis (scarring of liver tissue).

At 48 weeks, 70.8 percent of patients in the Viread arm (n=250) had a complete response compared to 48.8 percent in the Hepsera arm (n=125; p less than 0.001). The most commonly observed treatment-emergent adverse events of moderate intensity or higher were abdominal pain, back pain, headache, respiratory infections, creatinine phosphokinase and transaminase elevations. The incidence of these events was comparable between the Viread and Hepsera arms of the study. In addition, the incidence of grade 3 or 4 laboratory abnormalities was comparable between the two arms. Full study results will be submitted for presentation at an upcoming scientific meeting.

"Chronic hepatitis B remains a serious disease that impacts more than one million people in the United States and an estimated 400 million people worldwide," said Franck Rousseau, MD, Vice President, Clinical Research, Gilead Sciences.
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: North America Laparoscopes Market Outlook ... North America Laparoscopes Market Outlook to ... America Laparoscopes Market Outlook to 2020", provides key ... The report provides value, in millions of US ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Reimbursement Landscape Poland " an essential source of ... healthcare market and provides insights into the demographic, ... the report provides valuable insights into the trends ...
(Date:8/28/2014)... China , Aug. 28, 2014 ... TPI ), a pharmaceutical company that specializes in ... generics and active pharmaceutical ingredients (API) today updates ... Company,s Qionglai Facility (QLF). The ... Practice (GMP) dataset for China Food & Drug ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Reportlinker.com announces that a new market research ... Patient Self-Monitoring: Devices, Markets, Players ... http://www.reportlinker.com/p0581171/Patient-Self-Monitoring-Devices-Markets-Players-and-Prospects .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic The ... serum levels is deemed to be a ...
... A new patent covering tumor suppression technologies, including the ... awarded to The University of Texas System ... to the discovery that chromosome 3p21.3 genes act as ... also known as FUS1, the anti-cancer agent in ...
Cached Medicine Technology:Patient Self-Monitoring: Devices, Markets, Players and Prospects 2Patient Self-Monitoring: Devices, Markets, Players and Prospects 3Genprex Announces New Patent Issuance in Japan 2
(Date:8/28/2014)... Wilmington, DE (PRWEB) August 28, 2014 Blood's ... murder, gunplay, sex, money and family ties in the heart ... like no other – a story about how disrespect caused ... and limbs on many streets. , The Yayo Boyz and ... leave news reporters speechless and local onlookers in a silent ...
(Date:8/28/2014)... Arizona State University graduate student Anthony Gonzales, co-founder ... one of five finalists in Entrepreneur magazine’s 2014 College ... fourth consecutive year that an ASU student has been ... SafeSIPP, and JJ Tang, co-founder of Vantage Realized, were ... dominated the competition: Three of the five finalists were ...
(Date:8/28/2014)... -- Arguments between parents may damage their relationships with ... more than 200 families were asked to make daily ... each day, mothers and fathers rated the quality of ... On days when parents reported conflict and tension in ... strained, according to the study recently published in the ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ABC television ... the 49th MDA Show of Strength Telethon airing Sunday, ... country to help raise funds and awareness to help ... affected by muscle disease. , Viewers tuning into the ... enjoy heart-felt appeals and introductions from some of the ...
(Date:8/28/2014)... Governor of Yucatán, Rolando Zapata Bello, presented the ... event is organized by the Microcredit Summit Campaign in ... Microenterprise Financing Program ( PRONAFIM ) and will take ... Convention Center Yucatan Siglo XXI in the city of ... to host the 17th Microcredit Summit logistically but especially ...
Breaking Medicine News(10 mins):Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 3Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3
... Cannabis was well-tolerated, effective when added to existing ... News) -- Medicinal marijuana helps relieve neuropathic pain ... California, San Diego, School of Medicine study. , ... that wasn,t adequately controlled by opiates or other ...
... ... PALM BEACH, Fla., Aug. 6 The Breakers Palm ... but a company,deeply committed to each employee,s personal well-being. The ... the best of Florida,s,growing season exclusively for The Breakers, 2,300 ...
... Aduromed Begins Next Step in Corporate Evolution, Restructuring the Company ... and Augmenting its Board and Management Team, ... Board: ADRM) a leading manufacturer of medical waste,treatment systems, today ... raise of $3.8 million of new equity capital. As,part of ...
... PLC Systems Inc.,(Amex: PLC ), a company focused ... financial results for the three,and six month periods ended ... were $1,310,000 compared with,$1,932,000 in the second quarter of ... was $671,000, or $0.02 per diluted share, compared to ...
... - Mylan Increases Adjusted EPS Guidance for 2008 to $0.47 ... ... MYL ),today announced its financial results for the three and six months ended,June ... the three months ended June 30,2008, which excludes the impact of certain purchase ...
... ... Second Quarter 2008 Highlights:, ... of $27.4 million, up 86.3% over second quarter 2007,- Gross margin of 25.0%, up from 21.1% in the ... in the first quarter of 2008, - Operating ...
Cached Medicine News:Health News:Medicinal Marijuana Eases Neuropathic Pain in HIV 2Health News:Luxury Resort Operates Seasonal Green Market for 2,300 Staff 2Health News:Aduromed Closes Restructuring and Raises $3.8 Million of New Equity Capital 2Health News:Aduromed Closes Restructuring and Raises $3.8 Million of New Equity Capital 3Health News:PLC Systems Reports Second Quarter 2008 Results 2Health News:PLC Systems Reports Second Quarter 2008 Results 3Health News:PLC Systems Reports Second Quarter 2008 Results 4Health News:PLC Systems Reports Second Quarter 2008 Results 5Health News:PLC Systems Reports Second Quarter 2008 Results 6Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 2Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 3Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 4Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 5Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 6Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 7Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 8Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 9Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 10Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 11Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 2Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 3Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 4Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 5Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 6Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 7Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 8Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 9